Skip to main content
ISTH 2023 Main banner
Back

    Dan Bloomfield, MD (he/him/his)

    Chief Medical Officer
    Anthos Therapeutics, Inc.
    Cambridge, Massachusetts, United States

    Daniel M. Bloomfield M.D. is the Chief Medical Officer of Anthos Therapeutics where he leads an extraordinary team of clinical scientists and clinical operations professionals. Prior to joining Anthos, Dan helped create Cardurion Pharmaceutical in May 2017 as its first Chief Executive Officer.

    Prior to moving to Cardurion, Dan had a 14 year career at Merck and Co. culminating as Senior Vice President, Global Clinical Development at Merck Research Laboratories, Therapeutic Area Head for Cardiovascular, Diabetes, Endocrine, and Women’s Health and he was responsible for the central coordination and strategic oversight of Merck’s R&D organization in China across all therapeutic areas. Dan joined Merck Research Laboratories in 2003 and enjoyed a diverse career that included leadership roles in cardiovascular Discovery, as well as early and late clinical development, active involvement in business development, acquisitions, and numerous licensing opportunities. In addition to his executive duties, Dr. Bloomfield was a founding member and co-chair of the Cardiac Safety Research Consortium (a public private partnership with the FDA, academia and industry). Dr. Bloomfield also served as Rapporteur for the ICH E14 implementation working group for 9 years.

    After finishing a BA in Chemistry at Haverford College, Dan took a Master's degree in Social Anthropology at the University of Oxford as a Rhodes Scholar, attended Harvard Medical School and subsequently did his Internal Medicine and Cardiology training at Columbia before joining the faculty. As an Associate Professor of Medicine in the Division of Cardiology, his academic research was supported by grants from the NIH (K08, R01, K24), multiple foundations, and industry. He became recognized internationally as an expert in syncope (fainting spells), as well as novel methods used to identify patients at risk for sudden cardiac death.

    Presentation(s):